Literature DB >> 29231198

Prostate cancer in 2017: Advances in imaging.

Andreas G Wibmer1, Hebert Alberto Vargas1, Hedvig Hricak1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29231198      PMCID： PMC6673661          DOI： 10.1038/nrurol.2017.210

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Authors:  Silke Gillessen; Gerhardt Attard; Tomasz M Beer; Himisha Beltran; Alberto Bossi; Rob Bristow; Brett Carver; Daniel Castellano; Byung Ha Chung; Noel Clarke; Gedske Daugaard; Ian D Davis; Johann de Bono; Rodolfo Borges Dos Reis; Charles G Drake; Ros Eeles; Eleni Efstathiou; Christopher P Evans; Stefano Fanti; Felix Feng; Karim Fizazi; Mark Frydenberg; Martin Gleave; Susan Halabi; Axel Heidenreich; Celestia S Higano; Nicolas James; Philip Kantoff; Pirkko-Liisa Kellokumpu-Lehtinen; Raja B Khauli; Gero Kramer; Chris Logothetis; Fernando Maluf; Alicia K Morgans; Michael J Morris; Nicolas Mottet; Vedang Murthy; William Oh; Piet Ost; Anwar R Padhani; Chris Parker; Colin C Pritchard; Mack Roach; Mark A Rubin; Charles Ryan; Fred Saad; Oliver Sartor; Howard Scher; Avishay Sella; Neal Shore; Matthew Smith; Howard Soule; Cora N Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew R Sydes; Ian Tannock; Bertrand Tombal; Riccardo Valdagni; Thomas Wiegel; Aurelius Omlin
Journal:  Eur Urol       Date:  2017-06-24       Impact factor: 20.096

2.  68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Finn E von Eyben; Maria Picchio; Rie von Eyben; Handoo Rhee; Glenn Bauman
Journal:  Eur Urol Focus       Date:  2016-11-15

Review 3.  What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Authors:  Paul C Moldovan; Thomas Van den Broeck; Richard Sylvester; Lorenzo Marconi; Joaquim Bellmunt; Roderick C N van den Bergh; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Theo H van der Kwast; Vsevolod B Matveev; Henk G van der Poel; Maria De Santis; Ivo G Schoots; Thomas Wiegel; Cathy Yuhong Yuan; Philip Cornford; Nicolas Mottet; Thomas B Lam; Olivier Rouvière
Journal:  Eur Urol       Date:  2017-03-21       Impact factor: 20.096

4.  (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.

Authors:  Cristina Nanni; Lucia Zanoni; Cristian Pultrone; Riccardo Schiavina; Eugenio Brunocilla; Filippo Lodi; Claudio Malizia; Matteo Ferrari; Patrizio Rigatti; Cristina Fonti; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-10       Impact factor: 9.236

5.  Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?

Authors:  Hebert Alberto Vargas; Alexandre G Martin-Malburet; Toshikazu Takeda; Renato B Corradi; James Eastham; Andreas Wibmer; Evis Sala; Michael J Zelefsky; Wolfgang A Weber; Hedvig Hricak
Journal:  Urol Oncol       Date:  2016-06-23       Impact factor: 3.498

6.  Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies.

Authors:  Nicolas Barry Delongchamps; Michaël Peyromaure; Alexandre Schull; Frédéric Beuvon; Naïm Bouazza; Thierry Flam; Marc Zerbib; Naira Muradyan; Paul Legman; François Cornud
Journal:  J Urol       Date:  2012-10-08       Impact factor: 7.450

7.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study.

Authors:  Philippe Puech; Olivier Rouvière; Raphaele Renard-Penna; Arnauld Villers; Patrick Devos; Marc Colombel; Marc-Olivier Bitker; Xavier Leroy; Florence Mège-Lechevallier; Eva Comperat; Adil Ouzzane; Laurent Lemaitre
Journal:  Radiology       Date:  2013-04-11       Impact factor: 11.105

8.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

9.  Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).

Authors:  Rita Faria; Marta O Soares; Eldon Spackman; Hashim U Ahmed; Louise C Brown; Richard Kaplan; Mark Emberton; Mark J Sculpher
Journal:  Eur Urol       Date:  2017-09-19       Impact factor: 20.096

10.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Authors:  Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-12       Impact factor: 9.236
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.